SNAP Vaccine Platform

The SNAP (Spontaneous Nanoliposome Antigen Particleization) platform technology is a unique liposome-based system that functions as a potent vaccine adjuvant designed to address functional and practical limitations facing vaccine development.

Recombinant proteins and peptides represent a safe and simple method of vaccine production with the added benefits of defined antigenicity, rapid manufacturing and scale up. However, recombinant proteins often fail to produce a robust immune response, leading to a lack of protection against the disease of interest.  In order to generate a viable immune response, antigens are often coupled to immunogenic carriers,  nanoparticles, or engineered into virus-like particles, a labor-intensive process with significant detriments for vaccine development and manufacturing. The SNAP platform seeks to address these limitations by providing a novel nanoparticle platform that has the functional simplicity of conventional vaccine adjuvants.


The SNAP approach involves simple incubation of His-tagged antigens with SNAP-liposomes (Figure 1A), leading to the insertion of the His-tagged antigen into the bilayer and coordination with cobalt chelated in the porphyrin lipid, forming a His-tag membrane anchor (Figure 1B).


Illustration of the SNAP approach

Influenza virus HA admixed with SNAP liposomes

Instantly Harness the Power of Particle-Based Vaccines

• SNAP liposomes contain Cobalt porphyrin phospholipid (CoPoP) and the lipid adjuvants synthetic MPLA and optionally QS-21

• CoPoP enables rapid and biostable display of antigens on liposomes with simple mixing.

•SNAP focuses the immune response on antigen of interest with protein-free scaffold technology

•Requires a conventional his-tagged antigen (4-10X) for usage

Potent, sustained
immune responses

•SNAP enhances antibody responses for his-tagged protein and peptide antigens

• Antibody half-life in mice demonstrated to approach one year in multiple studies

• Strong cellular responses also observed

 Straightforward Multiplexing


• SNAP is ideal for multivalent immunization.

• SNAP demonstrated for 10-plex protein antigens

• A single peptide in a SNAP vaccine remained even when multiplexed with 59 other peptides.

Mechanism of potency

• SNAP provides improved depot effect and better uptake of antigens by immune cells in the lymph node

• Co-delivery of adjuvants along with antigens to same immune cells further enhance immune response

Clinical-stage, versatile adjuvant system

• Part of EuCorVac-19, tested in a 280 person Phase I/II trial; Phase III trials commenced.

• CoPoP produced under GMP at 2.5M dose scale. Other components are available under GMP.
• Compatible and with pre-mixing, two-vial mixing, and lyophilization

Seeking collaboration to assess SNAP technology

•POP BIO holds exclusive license to the SNAP patent portfolio
•Excellent results obtained independently by > 5 separate collaborators
•SNAP liposomes, controls, and simple assays for characterizing particles ready to ship out

POP BIO seeks collaborators around the SNAP platform
Contact us to setup receipt of a sample today!

POP BIO holds exclusive global license to the SNAP patent portfolio and has excellent results obtained, independently, with numerous active collaborations with a variety of industry partners.

SNAP Liposomes, controls, and simple assays for characterization are ready for immediate transfer and shipment.